DexCom director sells 1,012 shares at $58.07 under 10b5-1 plan
DexCom (DXCM) director Bridgette P. Heller reported an open-market sale of 1,012 common shares at $58.07 on November 12, 2025, executed under a Rule 10b5-1 trading plan adopted on August 14, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
DexCom (DXCM) director Bridgette P. Heller reported an open-market sale of 1,012 common shares at $58.07 on November 12, 2025, executed under a Rule 10b5-1 trading plan adopted on August 14, 2025.
Following the transaction, she beneficially owns 27,031 shares directly, which include 5,046 unvested RSUs granted May 8, 2025 that vest on the earlier of the one-year anniversary or DexCom’s 2026 annual meeting.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,012 | $58.07 | $59K |
Footnotes (2)
- F1. On August 14, 2025, Ms. Heller adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Heller. The shares set forth above were sold pursuant to the 10b5-1 Plan.
- F2. Included in this number are 5,046 unvested restricted stock units which were granted on May 8, 2025 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did DexCom (DXCM) disclose in this Form 4?
What RSUs are included in the ownership figure for DXCM?
When will the reported RSUs vest for DXCM?
What is the reporting person’s role at DexCom?
AI-generated analysis. How Rhea-AI works. Not financial advice.